Skip To Main Content
Aying Ma on Muck Rack

Aying Ma

As seen in: Nature, Cell Reports Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Aying

Contact Aying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Activation of Nerve Growth Factor signaling limits the response to lenvatinib in hepatocellular carcinoma

|
By Minghao Xu, Yimin Zheng, Longtao Zhao, Siwei Wang, Junbo Chen, Aying Ma, Bugang Liang, Yilan Huang, Haihan Xu, YUE WANG, Haiying Zeng, Chao Gao, Jiabin Cai, Aiwu Ke, Jia Fan, Zhongchi Fu, Yingjie Ai
| Nature Verified
Abstract Resistance to lenvatinib remains a major barrier in the treatment of advanced hepatocellular carcinoma (HCC), underscoring the urgent need to elucidate the underlying mechanisms and identify actionable therapeutic targets. In this study, we identified a neurosecretory factor derived from HCC cells, Nerve Growth Factor (NGF), as a critical mediator of lenvatinib resistance.
Open in Who Shared Issue with article?

CLDN4 palmitoylation promotes hepatic-to-biliary lineage transition and lenvatinib resistance in hepatocellular carcinoma

|
By Minghao Xu, Yimin Zheng, Junbo Chen, Chao Gao, Miao Zhu, Wenxin Xu, Jia Fan, Haibo Zhou, Yinghao Shen, Aying Ma, Bugang Liang, Aiwu Ke
| Cell Reports Medicine Verified
Keywords: Claudin4 hepatic-to-biliary transition lenvatinib resistance palmitoylation hepatocellular carcinoma Introduction Lineage transition is an intricate and poorly understood process in which the original lineage of a cancer undergoes alteration, leading to the emergence of a new cancer lineage. Due to the dynamic nature of cancer, tumor cell subpopulations evolve continuously throughout malignant progression and systemic treatment.
Open in Who Shared Issue with article?
See all 2 articles